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ess: fannyko@cuhk.eduSummary Chronic obstructive pulmonary disease (COPD) patients have increased
neutrophils and macrophages in their lungs, and inflammation of the airway is
related to oxidative stress. This study assessed the levels of 8-isoprostane (an
oxidative stress marker) and chemokines related to neutrophil and monocyte
inflammation (growth-related oncogene a [GROa] and monocyte chemoattractant
protein-1 [MCP-1]) in the airway of ex-smoking COPD patients by exhaled breath
condensate (EBC) collection.
Thirty-two (28 males) stable COPD patients (14 with FEV1 X50% [Group 1], 18
with FEV1 o50% predicted [Group 2]) and 18 non-smoking age and sex-matched
controls were studied in this cross-sectional study. EBC was collected using the
EcoScreen (Jaeger, Germany) during 10min of tidal breathing with the nose clipped.
Concentrations of 8-isoprostane, GROa and MCP-1 were measured by enzyme
immunoassays.
COPD patients had a higher concentration of 8-isoprostane than controls (COPD
versus control, Po0:001; Group 1 versus Group 2, P ¼ 0:045). 8-isoprostane
increased across the groups from normal, Group 1 to Group 2 (r ¼ 0:64, Po0:001).
The median intraquartile range (IQR) levels in pg/ml for GROa were 45.3(44.5–46.5),
45.4(44.5–46.0), 46.0(45.6–47.3), whereas MCP-1 levels were 5.3(5.2–5.9),
6.2(5.4–6.9) and 5.7(5.5–6.4) in Group 1, Group 2 COPD and control subjects,Elsevier Ltd. All rights reserved.
322195; fax: +852 26375396.
.hk (F.W.S. Ko).
ARTICLE IN PRESS
Exhaled breath condensate levels in COPD 631respectively. GROa level was lower in COPD patients when compared to controls
(P ¼ 0:01). MCP-1 level did not differ between COPD and the control group.
8-isoprostane level, but not GROa and MCP-1, in EBC was increased in COPD
patients with poorer lung function. This suggests an increased oxidative stress in the
airway in patients with more severe COPD.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Increased oxidative stress1 and leukocyte infiltra-
tion in the airway2 are observed in patients with
chronic obstructive pulmonary disease (COPD).
Imbalance between oxidants and anti-oxidants in
the airway may play an important role in the
pathogenesis of COPD.1 Oxidative stress leads to
the formation of isoprostanes by the free radical-
catalyzed peroxidation of arachidonic acid.3 8-
isoprostane, a member of the F2 isoprostane class,
is increased in urine4 and in exhaled breath
condensate (EBC) of stable COPD patients who are
current smokers when compared to healthy smo-
kers.5
Patients with COPD have increased neutrophils
and macrophages in the bronchoalveolar lavage
fluid (BALF) in comparison to healthy control
subjects.6,7 More neutrophils are found in induced
sputum of COPD patients than in normal sub-
jects,8,9 whereas the number of macrophages is
increased 5–10 times in the BALF of patients with
COPD.7,10 Chemokines are very small molecules
with a molecular weight of about 8 kDa and are a
family of cytokines with strong chemoattractant
properties. Specific chemokines may be involved in
the influx of inflammatory cells into the airway.
Growth-related oncogene (GROa) is a CXC che-
mokine and is first described as a mitogen for
human melanoma cells.11 It is a powerful activator
for neutrophils and has chemotactic ability for T-
lymphocytes, basophils and neutrophils.11–13 It is
produced by different cells including monocytes,
endothelial cells, epithelial cells and alveolar
macrophages.14–16 It would be detected in the
BALF in human lungs.17 Monocyte chemoattractant
protein-1 (MCP-1) is a 8.7 kDa CC chemokine that
induces chemotaxis of human monocytes/macro-
phages and a subset of human T-lymphocytes.18–20
It is produced by monocytes, T-lymphocytes,
fibroblasts, endothelial cells and smooth muscles
cells.21,22 Previous studies have found that patients
with chronic bronchitis have higher MCP-1 in the
BALF than healthy non-smokers.23 In bronchial
biopsy specimens, MCP-1 mRNA bronchiolar epithe-
lium expression, including the expression of its
receptor (CCR2 in macrophages), was increased in
COPD patients when compared to subjects withoutCOPD.22 The level of GROa and MCP-1 in sputum
samples, but not BALF, of smoking COPD patients
were also increased when compared to non-
smokers and healthy smokers.24 These chemokines
may contribute to the inflammatory load associated
with COPD.
Our group has demonstrated that T cell-specific
chemokines, like macrophage-derived chemokine,
could be measured in the EBC of paediatric
asthmatic subjects with higher levels than the
controls.25 Eotaxin, one of the major chemotactic
factors for eosinophils, could also be measured in
virtually all subjects. However, it is not sure
whether chemokines related to neutrophilic and
monocytic inflammation like GROa and MCP-1 can
be detected in the EBC of COPD patients.
The aim of this study is to assess the level of
oxidative stress and inflammation in the airway
non-invasively by collection of EBC. The levels of 8-
isoprostane, GROa and MCP-1 were measured in
both COPD patients and controls and the relation-
ship between their levels, lung function and
dyspnoea score was assessed.Materials and methods
Study population
Thirty-two COPD patients were recruited from the
respiratory clinic and the general medical clinic of
the Prince of Wales Hospital, Hong Kong. All the
subjects had a diagnosis of COPD according to the
Global Initiative of Obstructive Lung Disease Guide-
line26 and were on bronchodilator treatment. In
addition, all their previous lung function studies did
not show significant reversibility to bronchodilator
(forced expiratory volume in 1 s (FEV1) increased by
less than 200ml and 15% of baseline value after
400mcg of salbutamol). Their chest radiographs
also showed no obvious radiographic evidence of
fibrosis or bronchiectatic changes. All these pa-
tients were ex-smokers (at least 3 months) with at
least 10 pack years of smoking history. All patients
were not on aspirin, non-steroidal anti-inflamma-
tory agents or systemic steroids. They also had
neither intercurrent infection nor exacerbation,
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airway disease for at least 8 weeks prior to the
study. Age and sex matched non-smoking subjects
with no known chronic respiratory diseases and
recent respiratory symptoms for at least 8 weeks
were recruited as controls. These control subjects
were participants of another project in our unit.
They were healthy non-smoking persons from the
community who were selected by random tele-
phone digit dialing and invited to have lung
function assessment.
The study protocol was approved by the Research
Ethics Committee of the Chinese University of Hong
Kong and each subject had given informed written
consent.
Lung function, 6min walk test and dyspnoea
score measurement
Spirometry (Vitalograph, Model S, UK) was per-
formed on all subjects to determine their lung
function according to the American Thoracic
Society (ATS) standards.27 FEV1 and forced vital
capacity (FVC) were measured pre- and post-
bronchodilator therapy (salbutamol 400mcg). A 6-
min walk test was performed after spirometry
according the ATS guidelines.28 The subjective
degree of dyspnoea after the 6-min walk test was
assessed by the Borg score (score from 0 to 10).29
Collection of exhaled breath condensate
EBC was collected using the EcoScreen (Jaeger,
Germany) according to manufacturer instructions.
The collection was done from 9 to 10 am in the
morning. After rinsing their mouth, the recruited
subjects breathed tidally through a mouthpiece
that was connected through a unique one-way
valve into a cooled collection tube where vapors,
aerosols and moisture in the breath condensed
along the walls of the tube. The design of the
system prevents salivary contamination of EBC.
Each subject was asked to breathe through the
collection kit for 10min while wearing a noseclip
with more than 1ml of EBC collected. EBC was
stored immediately at 70 1C until analysis.
Measurement of 8-isoprostane, MCP-1 and
GROa
The concentrations of 8-isoprostane, MCP-1 and
GROa in the frozen EBC were measured in one
batch. Concentrations of these markers were
measured by sandwich enzyme immunoassays (8-
isoprostane from Cayman Chemical, Ann Arbor, MI,USA; MCP-1 and GROa from R & D Systems,
Minneapolis, MN, USA) according to instructions
provided by the manufacturers. The specificity of
8-isoprostane assay was 100%. The intra-assay and
inter-assay variabilities of 8-isoprostane, MCP-1
and GROa were o10%. The sensitivities of this
method for 8-isoprostane, MCP-1 and GROa were 4,
5 and 10 pg/ml, respectively.
Assessment of reproducibility of the exhaled
chemokine and 8-isoprostane measurements
Intra-subject reproducibility of 8-isoprostane, MCP-
1 and GROa was assessed by collection of EBC in
healthy volunteers working in the investigator’s
laboratories. A total of 10 subjects had EBC
collected as described above at the same time
(09:00 to 10:00) for 2 consecutive days. All subjects
had no known respiratory disease and were free
from symptoms of respiratory tract infection or
medication use at least 4 weeks prior to study.
Statistical analysis
Data were analyzed by the Statistical Package of
the Social Science (SPSS) Statistical software for
Window version 11.5 (SPSS Inc, Chicago, IL, USA).
Demographic data of the subjects were presented
as means7standard deviation (SD). The 8-isopros-
tane, GROa and MCP-1 levels were expressed as
median and interquartile range (IQR). When their
levels were below the detection limit of the
sandwich enzyme immunoassay kits, half of the
values of the lower detection limit would be taken
for statistical analysis. A P-value o0.05 was
considered as statistically significant. The 8-iso-
prostane, GROa and MCP-1 levels were compared
between the COPD patients and control groups by
Kruskal–Wallis test or Mann–Whitney rank sum test
as appropriate. Correlation of lung function,
symptoms and peripheral white cell count with
the levels of exhaled breath markers were assessed
by Spearman’s rank correlation test. Bland and
Altman’s method was used to assess repeatability
of 8-isoprostane, GROa and MCP-1 in the EBC.30Results
Demographic data of the patients are shown in
Table 1. Patients with COPD were divided into two
groups. Group 1 had mild-to-moderate COPD with
FEV1X50% predicted. Group 2 COPD had severe
COPD with FEV1o50% predicted normal. Among the
COPD patients, 21 (66%) and 11 (34%) were on
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Table 1 Demographics of the COPD and control subjects.
All COPD patients
(n ¼ 32)
COPD patients
with FEV1X50%
predicted (Group
1 COPD) (n ¼ 14)
COPD patients
with FEV1o50%
predicted (Group
2 COPD) (n ¼ 18)
Control subjects
(n ¼ 18)
Age (year) 7279 7276 72711 7375
Sex (M/F) 28/4 13/1 15/3 13/5
FEV1 (l) 0.9770.49
 1.3970.45] 0.6570.17 1.9570.43
FEV1% predicted 51.5722.4
 72.2716.1] 35.379.5 121.6721.3
FVC (l) 1.7370.65 2.1370.66] 1.4270.45 2.2270.50
FVC % predicted 64.5719.3 78.3717.5] 53.8712.9 97.2717.6
FEV1/FVC 55.9715.0
 65.7711.0] 48.3713.4 87.874.1
Smoking habits (pack-year) 41.5724.3 34.8719.2 45.6727.0 0
Duration of smoking
cessation (year)
8.6710.3 8.978.4 8.4711.6 —
BMI (kg/m2) 22.874.6 23.774.1 22.074.9 25.672.2
Blood neutrophil count
( 109/l)
4.9872.36 4.1471.37 5.6372.77 4.0371.24
Blood eosinophil count
( 109/l)
0.2870.22 0.2770.18 0.2970.25 0.1770.15
Blood monocyte count
( 109/l)
0.5470.21 0.5370.23 0.5570.19 0.4670.18
6min walk test (m) 288.37113.5 314.17132.8 268.2795.0 —
Borg score 4.073.4 1.472.4] 6.172.5 0
ICS use (n) 21 8 13 0
Theophylline use (n) 11 4 7 0
Data were presented as mean7SD.
P value o0.05 between COPD, and control groups
]P value o0.05 between Group 1 and 2 COPD.
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Figure 1 The level of 8-isoprostane in the exhaled breath
condensate of COPD and control subjects. Group 1: COPD
patients with FEV1X50%, Group 2: COPD patients with
FEV1o50%, For Group 1 and Group 2, non-filled symbols
represent those not on inhaled corticosteroid and filled
symbols represented those on inhaled corticosteroid——-
median level, ———— line represents the detection limit
of 8-isoprostane.
Exhaled breath condensate levels in COPD 633inhaled corticosteroid (ICS) and oral theophylline
treatment, respectively. For those patients who
were on ICS, the mean daily beclomethasone
equivalent dose was 1371.47546.0mcg. Group 1
COPD patients had a similar 6min walk distance as
the Group 2 COPD patients (P ¼ 0:06). However, the
Borg score was much higher in the Group 2 when
compared with the Group 1 COPD patients
(Po0:001). None of our subjects were on long term
oxygen therapy. The mean (SD) of the duration of
smoking cessation was 8.6(10.3) years.
The median [IQR] 8-isoprotane level in EBC of
COPD patients and controls were 14.2 [9.5–26.4]
and 6.0 [4.2–9.7] pg/ml, respectively, with a higher
level in the COPD patients than controls (Po0:001).
The data are shown in Fig. 1. Patients with more
severe COPD (Group 2 COPD) had a higher level of
8-isoprostane (19.3 [12.0–39.5] pg/ml) in the EBC
when compared to those with mild-to-moderate
COPD (Group 1 COPD) (12.5 [7.1–19.2] pg/ml,
P ¼ 0:045). 8-isoprostane level did not differ among
the COPD patients who were on ICS when compared
to those who were steroid naı¨ve (19.0 [10.7–40.0]
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Figure 3 The level of MCP-1 in the exhaled breath
condensate of COPD and controls subjects. Group 1:
COPD patients with FEV X50%, Group 2: COPD patients
F.W.S. Ko et al.634pg/ml for those on ICS and 12.6 [7.4–19.1] pg/ml in
the steroid naı¨ve group, P ¼ 0:09). 8-isoprostane
level in EBC did not correlate with FEV1/FVC ratio
(r ¼ 0:27, P ¼ 0:14), FEV1 percentage predicted
values (r ¼ 0:31, P ¼ 0:08), 6min walk distance
(r ¼ 0:07, P ¼ 0:72) and the degree of dyspnoea as
measured by the Borg score (r ¼ 0:29, P ¼ 0:12) in
COPD patients. However, if control subjects and
COPD subjects were all included in the analysis, 8-
isoprostane value showed a negative correlation
with the FEV1% predicted value (r ¼ 0:51,
Po0:001).
The median [IQR] GROa level was lower in the
EBC of COPD subjects than controls (45.4
[44.5–46.2] pg/ml versus 46.0 [45.6–47.3] pg/ml
respectively, P ¼ 0:02). The data are illustrated in
Fig. 2. There was no significant difference in EBC
GROa levels between Group 1 and Group 2 COPD
patients (45.3 [44.5–46.5] pg/ml versus 45.4
[44.5–46.0] pg/ml respectively, P ¼ 0:92). COPD
patients who were on ICS therapy did not differ in
their EBC GROa level when compared to the steroid
naı¨ve patients (45.8 [44.5–46.4] pg/ml in ICS group
versus 45.3 [44.5–45.5] pg/ml in steroid naı¨ve
group, P ¼ 0:20). EBC GROa level in COPD patients
did not correlate with the FEV1/FVC ratio
(R ¼ 0:02, P ¼ 0:91), FEV1 percentage predicted
value (r ¼ 0:146, P ¼ 0:43), Borg score (r ¼ 0:09,
P ¼ 0:66) or 6min walk distance (r ¼ 0:35,
P ¼ 0:06).0
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Figure 2 The level of GROa in the exhaled breath
condensate of COPD and control subjects. Group 1: COPD
patients with FEV1X50%, Group 2: COPD patients with
FEV1o50%, For Group 1 and Group 2, non-filled symbols
represent those not on inhaled corticosteroid and filled
symbols represented those on inhaled corticosteroid. NS:
no statistical significance, ——median level, ———— line
represents the detection limit of GROa.The median [IQR] MCP-1 level in EBC did not
differ between patients with COPD and controls
(5.7 [5.3–6.4] pg/ml versus 5.7 [5.5–6.4] pg/ml
respectively, P ¼ 0:94). The data are shown in
Fig. 3. Patients on ICS therapy did not differ in
their EBC MCP-1 levels when compared to steroid
naı¨ve COPD patients (6.0 [5.3–6.5] pg/ml versus 5.6
[5.3–6.4] pg/ml, respectively, P ¼ 0:50). In COPD
patients, MCP-1 level in EBC correlated with FEV1/
FVC ratio (r ¼ 0:48, P ¼ 0:01), but not with FEV1
percentage predicted value (r ¼ 0:18, P ¼ 0:32),1
with FEV1o50%, For Group 1 and Group 2, non-filled
symbols represent those not on inhaled corticosteroid
and filled symbols represented those on inhaled corti-
costeroid. NS: no statistical significance, ——median
level, ———— line represents the detection limit of
MCP-1.
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Figure 4 The relationship between MCP-1 level and
FEV1/FVC ratio of lung function in COPD subjects.
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Figure 6 Bland and Altman’s Plot of the repeatability of
condensate of controls.
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Figure 5 The relationship between 8-isoprostane level
and absolute monocyte count in peripheral blood of COPD
subjects.
Exhaled breath condensate levels in COPD 635Borg score (r ¼ 0:07, P ¼ 0:72) or 6min walk
distance (r ¼ 0:12, P ¼ 0:51). The relationship of
MCP-1 level with FEV1/FVC ratio is illustrated in
Fig. 4.
There was no correlation between the EBC levels
of 8-isoprostane, GROa and MCP-1. The EBC levels
of 8-isoprostane, GROa and MCP-1 did not correlate
with the differential white cell count in the
peripheral blood of COPD patent except that 8-
isoprostane correlated with the absolute monocyte
count in peripheral blood (r ¼ 0:51, P ¼ 0:01) and
the data are shown in Fig. 5.
Ten healthy adults (5 males and 5 females) aged
23–38 years had EBC collected and measured for
repeatability testing of the biomarkers. The differ-
ences between the majority of the paired measure-
ments laid within72 SDS (mean differences
0.0370.32, 1.3172.16, 0.4671.16 pg/ml for
8-isoprostane, GROa and MCP-1, respectively). TheMean of GRO alpha concentration (pg/ml)
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8-isoprostane, GROa and MCP-1 in the exhaled breath
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and MCP-1 were 6.7%, 2.6% and 10.6%, respectively.
Bland and Altman’s plots of the repeatability tests
are shown in Fig. 6.Discussion
This prospective, cross-sectional study has shown
that ex-smoking subjects with more severe COPD,
as reflected by FEV1 ofo50% predicted value, had a
higher level of 8-isoprostane level in EBC than
subjects with less severe COPD. We have also
demonstrated that the neutrophilic and monocytic
chemokines GROa and MCP-1 could be detected in
human EBC.
Our study concurred with previous studies that 8-
isoprostane was raised in the EBC of COPD patients
who were ex-smokers and current smokers when
compared to controls.31 Kostikas et al.5 found that
the level of 8-isoprostane was higher in the EBC of
COPD patients who were current smokers than the
smoking controls without COPD. In contrast to our
study, Kostikas et al. did not find a difference in the
EBC 8-isoprostane level in patients with different
severity of COPD stratified according to the FEV1%
predicted value. As currently smoking COPD sub-
jects were assessed in Kostikas’ study, it was
possible that continuous exposure to cigarette
smoke created an environment of high oxidative
stress and thus a high 8-isoprostane level in the
airway of COPD subjects with different spectrum of
disease severity. A previous study also suggested
that current healthy smokers without COPD had a
higher level of exhaled 8-isoprostane than healthy
non-smokers.31 Apart from cigarette smoking, a
recent study found that oxygen therapy, even as
short as an hour in duration, raised the oxidative
stress in the airway as reflected by the high exhaled
8-isoprostane and IL-6 values.32 In this current
study, ex-smoking COPD subjects, without the
continuous stimulation by oxygen or ingredients in
cigarette smoke, demonstrated a higher oxidative
stress in the airway, in the more severe COPD
patients as compared to the mild-to-moderate
cases. The level of 8-isoprostane in our COPD
patients was lower when compared to previous
study. In this current study, ex-smoking COPD
subjects had a level of 8-isoprostane at the order
of 10–20 pg/ml instead of about 40 pg/ml as in the
study by Montuschi et al.31 There was some
evidence to suggest that deficiency of anti-oxidant
defenses was related to the degree of airway
obstruction in patients with COPD33 and plasma
levels of anti-oxidants were found to decreaseduring periods of COPD exacerbations.34 It is
however unclear why oxidative stress in the airway
was higher in patients with poorer lung function or
whether anti-oxidants help improve lung function
of these ex-smoking COPD patients.35
This is the first study to demonstrate that
chemokines, like GROa and MCP-1, could be
detected in the EBC of COPD and normal subjects.
We have also demonstrated that GROa and MCP-1
could be measured in the EBC with good reprodu-
cibility in control subjects. Cells such as neutrophils
and monocytes are involved in the airway inflam-
mation in COPD patients. GROa and MCP-1 are the
chemokines involved in the recruitment of neutro-
phils and monocytes. Their small molecular weight
is likely the reason that they can be detected in the
EBC. Previous studies reported that both GROa and
MCP-1 level were increased in induced sputum,24
but not in BALF,17,24 of currently smoking COPD
patients in comparison to healthy smoking and non-
smoking controls. Our study on the EBC GROa level
in contrast has revealed that its level was margin-
ally lower in ex-smoking COPD patients than that of
non-smoking controls. GROa is a potent growth
promoting chemokine which is involved in pro-
cesses like keratinocyte proliferation and angiogen-
esis.36 Witherden et al., in their study of human
bronchial biopsy specimen, found that cigarette
smoke extract suppressed GROa in alveolar type II
epithelial cell culture.37 Previous studies on CXCR2
knockout mice36 and damaged human tissue38
suggested that GROa and IL-8 probably played a
role in growth and repair processes of the lung. In
ex-smoking COPD subjects, other uncertain me-
chanisms, in addition to the effect of cigarette
smoke, may be operating in the airway to suppress
the repairing process of lung tissue and contribute
to a persistent inflammation in the airway.
It is interesting to note that MCP-1 levels in the
EBC from COPD patients correlated with the degree
of airflow obstruction as measured by FEV1/FVC
ratio in this study. There are conflicting results in
the literature about the level of MCP-1 in the
airway. Capelli et al.23 reported that MCP-1 was
increased in the BALF of chronic bronchitic
patients. However, the same observation was not
detected by Traves et al.24 Increased MCP-1 was
noted in the induced sputum of smoking COPD
patients.24 In bronchiolar epithelial cells from
resected lung specimens, IL-8, macrophage inflam-
matory protein-1a, and MCP-1 mRNA levels were
higher in smokers with COPD than never-smokers or
smokers without either airflow limitation or em-
physema.39 MCP-1 mRNA expression in bronchiolar
epithelial cell of lung tissue correlated with its
receptor CCR2 expression on macrophages and
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induced sputum, BALF and biopsy samples different
compartments in the lungs and among these
methods, EBC seems a promising tool due to its
non-invasive nature. In the assessment of BALF,
sampling method including the volume of saline
used, may affect the yield of MCP-1 from the
alveoli and thus may not be a reliable tool for
assessment of chemokines in the airway.24 More
studies are needed to assess the role of MCP-1 in
the airway inflammation of COPD patients.
Previous studies found that ICS therapy in COPD
patients could not suppress the oxidative stress as
measured by 8-isoprostane in the EBC.5 In this
study, it was observed that ICS therapy in ex-
smoking COPD subjects could not suppress the
oxidative stress, neutrophils and monocytes-related
chemokines as measured by levels of 8-isoprostane,
GROa and MCP-1 in the EBC. This finding is expected
as it is known that ICS therapy does not modify the
rate of decline in lung function in all COPD
patients40–42 and ICS is not recommended for stable
COPD patients apart from those with poor lung
function and repeated exacerbations.26
One major limitation of this study was that we
relied on the patients’ self-reported smoking
status. Neither urine cotinine level nor exhaled
carbon monoxide level was assessed. As a result,
ex-smoking status of the patients could not be fully
ascertained.
In conclusion, in this study of the EBC collected
from ex-smoking COPD subjects, we have shown
that 8-isoprostane level was higher in patients with
more severe COPD (FEV1 o50% predicted) than
mild-to-moderate cases. The result suggests there is
more oxidative stress in patients with more severe
COPD and poorer lung function. The neutrophilic
and monocytic chemokines (GROa and MCP-1) could
be measured in the EBC. ICS had no effect on the
airway inflammatory markers measured in this
study. Further studies are needed to assess the role
of chemokines in the pathogenesis of COPD.Acknowledgement
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